[rev_slider alias=”slider-3-1″ slidertitle=”Home01″][/rev_slider]
What if we could reprogram aging cells in our body to fight disease and
enhance health?
CellRep uses AI to discover small molecules that rejuvenate immune cells — without genetic modification. Our lead application enhances CAR-T therapy against solid tumors, where current treatments fail 90% of the time. Applied ex vivo during manufacturing, our compounds act as reagents that require no separate drug approval. With a first-in-human trial planned for 2026, we’re building the platform for cellular rejuvenation — from cancer immunotherapy to longevity.
AI-powered discovery platform
From in silico prediction to in vivo validation
Experienced Team
Combined expertise in AI, cell biology, and successful entrepreneurship
Proven Results
6.6x improvement in T cell polyfunctionality
Established Traction
Research partnerships with leading institutions in the US, Colombia, and Brazil
Our
Approach
End-to-end pipeline from target discovery to preclinical validation of cell reprogramming strategies.
Non-genetic modification approach
Ex vivo manufacturing reagents — no separate drug approval required
From cancer immunotherapy to cellular longevity
Cells are nature’s supercomputers
A universe of opportunities holding the key to enhance our health.
AI models for target and drug discovery
0
+
Improvement in
T-Cell polyfunctionality
0
+
Provisional patents
filed
0
#
Antitumor capacity vs solid tumors
0
+
Layouts: Popup
Our Technology and Platform
We have developed an innovative approach to enhance T cell functionality by reprogramming these cells to a rejuvenated state and with improved therapeutic potential.
Our platform includes:
Target and Drug Discovery
Bioinformatics and AI-driven discovery of druggable targets
In vitro Screening
Optimized drug screening platform to analyze biomarkers at the single-cell level.
Preclinical testing
Cutting-edge in vivo models for PoC studies
Each cycle feeds back into the platform — biological results refine AI predictions, generating increasingly optimized compounds. Our compound series demonstrates this: each generation outperforms the last.
Meet our brilliant team
Our team is built of experienced immunologists, biochemists and bioinformatic engineers working together to deliver the best solutions to improve current and future cell therapies.
Alfonso Amat
CEO & Co-Founderlinkedin
Federico Perdomo Celis
CSO & Co-Founderlinkedin
Manuel Franco Cortés
CCO & Co-Founderlinkedin
Julian Ganzabal
CAIO & Co-Founderlinkedin
Prof. Luca Gattinoni
Advisorlinkedin
What’s the latest?
News, NoticiasApril 6, 2026501Views0Comments
Aging Is a Software Problem. We’re Writing the Patch.
How Nobel Prize science, AI, and small molecules are converging on…Read More
NewsOctober 2, 20256KViews0Comments
From Gstaad to the Future: Reflections on the Longevity Investors Conference
The Same Cellular “Software Bug” Affects Cancer, HIV, and Hepatitis Therapies…Read More
NewsSeptember 12, 20252KViews0Comments
Federico Perdomo and the persistence to open a place in immunology
This is a translation of the original article written by MARÍA…Read More
Contact Us